[丁丙诺啡用于治疗阿片类药物依赖：在社区药房进行的仿制药替代研究]
[Buprenorphine for the treatment of opioid dependence: a study on generic substitution conducted in community pharmacies].
作者信息
Julians-Minou Gaëlle, Bruch Sarah, Peyre Nathalie, Sudérie Guillaume, Lapeyre-Mestre Maryse, Roussin Anne
机构信息
Unité de Pharmacoépidémiologie, EA 3696, Université de Toulouse, Centre d'Evaluation et d'Information sur la Pharmacodépendance-Addictovigilance, Service de Pharmacologie Clinique, Hôpitaux de Toulouse, France.
出版信息
Therapie. 2010 May-Jun;65(3):241-7. doi: 10.2515/therapie/2010012. Epub 2010 Aug 11.
OBJECTIVE
To describe the evolution of buprenorphine prescription form characteristics before and after the application of a measure of the French Social Security system aimed to encourage the use of generic drugs.
METHOD
All buprenorphine prescription forms issued to sixty-two patients subjected to follow-up in 6 community pharmacies were analysed between October 2007 and February 2008.
RESULTS
Patients maintained on Subutex during the whole follow-up were more numerous (n=39), younger, and received a higher daily dose of buprenorphine (10.5 mg versus 7.8 mg), compared to patients maintained on generic (n=13). For patients receiving again Subutex after have been treated by a generic (n=10), daily doses remained unchanged.
CONCLUSION
It seems that the patients stabilized on generic present less serious pharmacodependence and less psychiatric comorbidity than those maintained on Subutex. Substituting a buprenorphine speciality with another should not induce any treatment unsettlement.
目的
描述法国社会保障系统一项旨在鼓励使用非专利药品的措施实施前后丁丙诺啡处方形式特征的演变。
方法
对2007年10月至2008年2月期间在6家社区药店接受随访的62名患者所开具的所有丁丙诺啡处方进行分析。
结果
与使用非专利药品的患者（n = 13）相比，在整个随访期间持续使用舒布酮的患者更多（n = 39），更年轻，且每日丁丙诺啡剂量更高（10.5毫克对7.8毫克）。对于在接受非专利药品治疗后再次使用舒布酮的患者（n = 10），每日剂量保持不变。
结论
似乎使用非专利药品稳定下来的患者与使用舒布酮的患者相比，药物依赖性较轻，精神合并症较少。用一种丁丙诺啡制剂替代另一种不应引起任何治疗不稳定情况。
Zotero 插件